nodes	percent_of_prediction	percent_of_DWPC	metapath
Dasatinib—FRK—female reproductive system—rectum cancer	0.00347	0.00675	CbGeAlD
Dasatinib—PKMYT1—female reproductive system—rectum cancer	0.00347	0.00675	CbGeAlD
Dasatinib—TESK1—seminal vesicle—rectum cancer	0.00344	0.00669	CbGeAlD
Dasatinib—STK36—seminal vesicle—rectum cancer	0.00338	0.00658	CbGeAlD
Dasatinib—BMPR1B—epithelium—rectum cancer	0.00324	0.0063	CbGeAlD
Dasatinib—TXK—female reproductive system—rectum cancer	0.00321	0.00624	CbGeAlD
Dasatinib—PTK6—female reproductive system—rectum cancer	0.00317	0.00618	CbGeAlD
Dasatinib—CSK—seminal vesicle—rectum cancer	0.00315	0.00613	CbGeAlD
Dasatinib—PKMYT1—vagina—rectum cancer	0.00314	0.00611	CbGeAlD
Dasatinib—HCK—seminal vesicle—rectum cancer	0.00311	0.00605	CbGeAlD
Dasatinib—ZAK—urethra—rectum cancer	0.00308	0.00599	CbGeAlD
Dasatinib—TEC—lymph node—rectum cancer	0.00301	0.00585	CbGeAlD
Dasatinib—STAT5B—female reproductive system—rectum cancer	0.003	0.00584	CbGeAlD
Dasatinib—ZAK—mammalian vulva—rectum cancer	0.00293	0.0057	CbGeAlD
Dasatinib—RIPK2—seminal vesicle—rectum cancer	0.00292	0.00569	CbGeAlD
Dasatinib—TXK—vagina—rectum cancer	0.0029	0.00564	CbGeAlD
Dasatinib—PTK6—vagina—rectum cancer	0.00287	0.00559	CbGeAlD
Dasatinib—BTK—mammalian vulva—rectum cancer	0.0028	0.00544	CbGeAlD
Dasatinib—TESK1—renal system—rectum cancer	0.00277	0.00539	CbGeAlD
Dasatinib—TESK1—urethra—rectum cancer	0.00272	0.0053	CbGeAlD
Dasatinib—SIK3—female reproductive system—rectum cancer	0.0027	0.00525	CbGeAlD
Dasatinib—STK36—urethra—rectum cancer	0.00268	0.00521	CbGeAlD
Dasatinib—EPHB3—urethra—rectum cancer	0.00268	0.00521	CbGeAlD
Dasatinib—CSK—smooth muscle tissue—rectum cancer	0.00264	0.00513	CbGeAlD
Dasatinib—FGR—seminal vesicle—rectum cancer	0.00259	0.00505	CbGeAlD
Dasatinib—TESK1—mammalian vulva—rectum cancer	0.00259	0.00504	CbGeAlD
Dasatinib—EPHB3—mammalian vulva—rectum cancer	0.00255	0.00496	CbGeAlD
Dasatinib—STK36—mammalian vulva—rectum cancer	0.00255	0.00496	CbGeAlD
Dasatinib—RIPK2—epithelium—rectum cancer	0.00254	0.00494	CbGeAlD
Dasatinib—CSK—renal system—rectum cancer	0.00254	0.00494	CbGeAlD
Dasatinib—ZAK—female reproductive system—rectum cancer	0.00251	0.00488	CbGeAlD
Dasatinib—CSK—urethra—rectum cancer	0.00249	0.00485	CbGeAlD
Dasatinib—EPHB4—seminal vesicle—rectum cancer	0.00247	0.00481	CbGeAlD
Dasatinib—LIMK2—mammalian vulva—rectum cancer	0.00246	0.0048	CbGeAlD
Dasatinib—HCK—urethra—rectum cancer	0.00246	0.00479	CbGeAlD
Dasatinib—JAK2—seminal vesicle—rectum cancer	0.00245	0.00477	CbGeAlD
Dasatinib—ERBB3—epithelium—rectum cancer	0.00243	0.00473	CbGeAlD
Dasatinib—EPHA2—seminal vesicle—rectum cancer	0.00242	0.00471	CbGeAlD
Dasatinib—FYN—seminal vesicle—rectum cancer	0.00242	0.00471	CbGeAlD
Dasatinib—BMPR1B—female reproductive system—rectum cancer	0.00241	0.00468	CbGeAlD
Dasatinib—MAP3K19—female reproductive system—rectum cancer	0.00241	0.00468	CbGeAlD
Dasatinib—CSK—mammalian vulva—rectum cancer	0.00237	0.00462	CbGeAlD
Dasatinib—MAP4K5—seminal vesicle—rectum cancer	0.00236	0.0046	CbGeAlD
Dasatinib—MAP3K3—seminal vesicle—rectum cancer	0.00236	0.0046	CbGeAlD
Dasatinib—TNK2—female reproductive system—rectum cancer	0.00236	0.00459	CbGeAlD
Dasatinib—EPHB1—lymph node—rectum cancer	0.00236	0.00459	CbGeAlD
Dasatinib—HCK—mammalian vulva—rectum cancer	0.00234	0.00456	CbGeAlD
Dasatinib—RIPK2—urethra—rectum cancer	0.00231	0.0045	CbGeAlD
Dasatinib—SIK1—renal system—rectum cancer	0.0023	0.00448	CbGeAlD
Dasatinib—ZAK—vagina—rectum cancer	0.00227	0.00442	CbGeAlD
Dasatinib—MAPK14—epithelium—rectum cancer	0.00226	0.0044	CbGeAlD
Dasatinib—SIK1—urethra—rectum cancer	0.00226	0.0044	CbGeAlD
Dasatinib—EPHB6—seminal vesicle—rectum cancer	0.00226	0.0044	CbGeAlD
Dasatinib—ERBB3—renal system—rectum cancer	0.00225	0.00439	CbGeAlD
Dasatinib—EPHA4—urethra—rectum cancer	0.00224	0.00435	CbGeAlD
Dasatinib—EPHA5—vagina—rectum cancer	0.00222	0.00432	CbGeAlD
Dasatinib—TESK1—female reproductive system—rectum cancer	0.00222	0.00432	CbGeAlD
Dasatinib—EPHB3—female reproductive system—rectum cancer	0.00218	0.00425	CbGeAlD
Dasatinib—STK36—female reproductive system—rectum cancer	0.00218	0.00425	CbGeAlD
Dasatinib—YES1—seminal vesicle—rectum cancer	0.00218	0.00425	CbGeAlD
Dasatinib—MAPK14—smooth muscle tissue—rectum cancer	0.00218	0.00424	CbGeAlD
Dasatinib—BTK—vagina—rectum cancer	0.00216	0.00421	CbGeAlD
Dasatinib—SIK1—mammalian vulva—rectum cancer	0.00215	0.00419	CbGeAlD
Dasatinib—EPHB4—epithelium—rectum cancer	0.00215	0.00418	CbGeAlD
Dasatinib—JAK2—epithelium—rectum cancer	0.00213	0.00415	CbGeAlD
Dasatinib—EPHA4—mammalian vulva—rectum cancer	0.00213	0.00414	CbGeAlD
Dasatinib—LIMK2—female reproductive system—rectum cancer	0.00211	0.00411	CbGeAlD
Dasatinib—EPHA2—epithelium—rectum cancer	0.0021	0.0041	CbGeAlD
Dasatinib—MAPK14—renal system—rectum cancer	0.0021	0.00409	CbGeAlD
Dasatinib—EPHB4—smooth muscle tissue—rectum cancer	0.00207	0.00402	CbGeAlD
Dasatinib—FGR—urethra—rectum cancer	0.00205	0.004	CbGeAlD
Dasatinib—LCK—urethra—rectum cancer	0.00205	0.004	CbGeAlD
Dasatinib—JAK2—smooth muscle tissue—rectum cancer	0.00205	0.00399	CbGeAlD
Dasatinib—STK35—female reproductive system—rectum cancer	0.00205	0.00398	CbGeAlD
Dasatinib—CSK—female reproductive system—rectum cancer	0.00203	0.00395	CbGeAlD
Dasatinib—FYN—smooth muscle tissue—rectum cancer	0.00202	0.00394	CbGeAlD
Dasatinib—TESK1—vagina—rectum cancer	0.00201	0.0039	CbGeAlD
Dasatinib—EPHB4—renal system—rectum cancer	0.00199	0.00387	CbGeAlD
Dasatinib—BMX—lymph node—rectum cancer	0.00198	0.00386	CbGeAlD
Dasatinib—MAP4K5—smooth muscle tissue—rectum cancer	0.00198	0.00385	CbGeAlD
Dasatinib—JAK2—renal system—rectum cancer	0.00198	0.00385	CbGeAlD
Dasatinib—STK36—vagina—rectum cancer	0.00197	0.00384	CbGeAlD
Dasatinib—EPHB3—vagina—rectum cancer	0.00197	0.00384	CbGeAlD
Dasatinib—BLK—lymph node—rectum cancer	0.00196	0.00381	CbGeAlD
Dasatinib—LCK—mammalian vulva—rectum cancer	0.00195	0.0038	CbGeAlD
Dasatinib—FGR—mammalian vulva—rectum cancer	0.00195	0.0038	CbGeAlD
Dasatinib—EPHB4—urethra—rectum cancer	0.00195	0.0038	CbGeAlD
Dasatinib—FYN—renal system—rectum cancer	0.00195	0.00379	CbGeAlD
Dasatinib—JAK2—urethra—rectum cancer	0.00194	0.00378	CbGeAlD
Dasatinib—MAP2K5—seminal vesicle—rectum cancer	0.00193	0.00376	CbGeAlD
Dasatinib—EPHA2—urethra—rectum cancer	0.00192	0.00373	CbGeAlD
Dasatinib—FYN—urethra—rectum cancer	0.00191	0.00373	CbGeAlD
Dasatinib—LIMK2—vagina—rectum cancer	0.00191	0.00371	CbGeAlD
Dasatinib—FMO3—mammalian vulva—rectum cancer	0.00189	0.00367	CbGeAlD
Dasatinib—RIPK2—female reproductive system—rectum cancer	0.00189	0.00367	CbGeAlD
Dasatinib—CSF1R—seminal vesicle—rectum cancer	0.00188	0.00367	CbGeAlD
Dasatinib—TXK—lymph node—rectum cancer	0.00188	0.00365	CbGeAlD
Dasatinib—MAP3K3—urethra—rectum cancer	0.00187	0.00364	CbGeAlD
Dasatinib—MAP4K5—urethra—rectum cancer	0.00187	0.00364	CbGeAlD
Dasatinib—EPHB4—mammalian vulva—rectum cancer	0.00186	0.00362	CbGeAlD
Dasatinib—STK35—vagina—rectum cancer	0.00185	0.0036	CbGeAlD
Dasatinib—JAK2—mammalian vulva—rectum cancer	0.00185	0.0036	CbGeAlD
Dasatinib—SIK1—female reproductive system—rectum cancer	0.00184	0.00358	CbGeAlD
Dasatinib—CSK—vagina—rectum cancer	0.00184	0.00358	CbGeAlD
Dasatinib—YES1—smooth muscle tissue—rectum cancer	0.00183	0.00356	CbGeAlD
Dasatinib—EPHA2—mammalian vulva—rectum cancer	0.00183	0.00355	CbGeAlD
Dasatinib—SRC—epithelium—rectum cancer	0.00182	0.00355	CbGeAlD
Dasatinib—EPHA4—female reproductive system—rectum cancer	0.00182	0.00355	CbGeAlD
Dasatinib—FYN—mammalian vulva—rectum cancer	0.00182	0.00355	CbGeAlD
Dasatinib—HCK—vagina—rectum cancer	0.00181	0.00353	CbGeAlD
Dasatinib—ERBB3—female reproductive system—rectum cancer	0.00181	0.00351	CbGeAlD
Dasatinib—ABL2—vagina—rectum cancer	0.0018	0.00351	CbGeAlD
Dasatinib—PDGFRA—smooth muscle tissue—rectum cancer	0.00179	0.00349	CbGeAlD
Dasatinib—MAP3K2—female reproductive system—rectum cancer	0.00179	0.00348	CbGeAlD
Dasatinib—EPHB6—urethra—rectum cancer	0.00179	0.00348	CbGeAlD
Dasatinib—MAP4K5—mammalian vulva—rectum cancer	0.00178	0.00347	CbGeAlD
Dasatinib—MAP3K3—mammalian vulva—rectum cancer	0.00178	0.00347	CbGeAlD
Dasatinib—YES1—renal system—rectum cancer	0.00176	0.00342	CbGeAlD
Dasatinib—SRC—smooth muscle tissue—rectum cancer	0.00176	0.00342	CbGeAlD
Dasatinib—STAT5B—lymph node—rectum cancer	0.00176	0.00342	CbGeAlD
Dasatinib—YES1—urethra—rectum cancer	0.00173	0.00336	CbGeAlD
Dasatinib—PDGFRA—renal system—rectum cancer	0.00173	0.00336	CbGeAlD
Dasatinib—KIT—seminal vesicle—rectum cancer	0.00171	0.00333	CbGeAlD
Dasatinib—RIPK2—vagina—rectum cancer	0.00171	0.00332	CbGeAlD
Dasatinib—EPHB6—mammalian vulva—rectum cancer	0.0017	0.00331	CbGeAlD
Dasatinib—SRC—renal system—rectum cancer	0.00169	0.00329	CbGeAlD
Dasatinib—MAPK14—female reproductive system—rectum cancer	0.00168	0.00327	CbGeAlD
Dasatinib—FGR—female reproductive system—rectum cancer	0.00167	0.00326	CbGeAlD
Dasatinib—PDGFRB—seminal vesicle—rectum cancer	0.00167	0.00325	CbGeAlD
Dasatinib—EPHA4—vagina—rectum cancer	0.00165	0.00321	CbGeAlD
Dasatinib—YES1—mammalian vulva—rectum cancer	0.00164	0.0032	CbGeAlD
Dasatinib—EPHA3—lymph node—rectum cancer	0.00162	0.00316	CbGeAlD
Dasatinib—EPHB4—female reproductive system—rectum cancer	0.00159	0.0031	CbGeAlD
Dasatinib—JAK2—female reproductive system—rectum cancer	0.00158	0.00308	CbGeAlD
Dasatinib—SIK3—lymph node—rectum cancer	0.00158	0.00307	CbGeAlD
Dasatinib—CSF1R—smooth muscle tissue—rectum cancer	0.00158	0.00307	CbGeAlD
Dasatinib—EPHA2—female reproductive system—rectum cancer	0.00156	0.00304	CbGeAlD
Dasatinib—FYN—female reproductive system—rectum cancer	0.00156	0.00304	CbGeAlD
Dasatinib—MAP2K5—urethra—rectum cancer	0.00153	0.00298	CbGeAlD
Dasatinib—MAP4K5—female reproductive system—rectum cancer	0.00153	0.00297	CbGeAlD
Dasatinib—MAP3K3—female reproductive system—rectum cancer	0.00153	0.00297	CbGeAlD
Dasatinib—MAPK14—vagina—rectum cancer	0.00152	0.00296	CbGeAlD
Dasatinib—FGR—vagina—rectum cancer	0.00151	0.00295	CbGeAlD
Dasatinib—LCK—vagina—rectum cancer	0.00151	0.00295	CbGeAlD
Dasatinib—CSF1R—urethra—rectum cancer	0.00149	0.0029	CbGeAlD
Dasatinib—ABL1—seminal vesicle—rectum cancer	0.00149	0.0029	CbGeAlD
Dasatinib—KIT—epithelium—rectum cancer	0.00149	0.00289	CbGeAlD
Dasatinib—ZAK—lymph node—rectum cancer	0.00147	0.00286	CbGeAlD
Dasatinib—FMO3—vagina—rectum cancer	0.00146	0.00285	CbGeAlD
Dasatinib—MAP2K5—mammalian vulva—rectum cancer	0.00146	0.00283	CbGeAlD
Dasatinib—PDGFRB—epithelium—rectum cancer	0.00145	0.00283	CbGeAlD
Dasatinib—EPHB4—vagina—rectum cancer	0.00144	0.00281	CbGeAlD
Dasatinib—KIT—smooth muscle tissue—rectum cancer	0.00143	0.00279	CbGeAlD
Dasatinib—JAK2—vagina—rectum cancer	0.00143	0.00279	CbGeAlD
Dasatinib—CSF1R—mammalian vulva—rectum cancer	0.00142	0.00276	CbGeAlD
Dasatinib—EPHA2—vagina—rectum cancer	0.00141	0.00275	CbGeAlD
Dasatinib—FYN—vagina—rectum cancer	0.00141	0.00275	CbGeAlD
Dasatinib—YES1—female reproductive system—rectum cancer	0.00141	0.00274	CbGeAlD
Dasatinib—BMPR1B—lymph node—rectum cancer	0.00141	0.00274	CbGeAlD
Dasatinib—BTK—lymph node—rectum cancer	0.0014	0.00273	CbGeAlD
Dasatinib—PDGFRB—smooth muscle tissue—rectum cancer	0.0014	0.00272	CbGeAlD
Dasatinib—PDGFRA—female reproductive system—rectum cancer	0.00138	0.00269	CbGeAlD
Dasatinib—TNK2—lymph node—rectum cancer	0.00138	0.00269	CbGeAlD
Dasatinib—MAP4K5—vagina—rectum cancer	0.00138	0.00268	CbGeAlD
Dasatinib—MAP3K3—vagina—rectum cancer	0.00138	0.00268	CbGeAlD
Dasatinib—KIT—renal system—rectum cancer	0.00138	0.00268	CbGeAlD
Dasatinib—SRC—female reproductive system—rectum cancer	0.00135	0.00264	CbGeAlD
Dasatinib—KIT—urethra—rectum cancer	0.00135	0.00264	CbGeAlD
Dasatinib—PDGFRB—renal system—rectum cancer	0.00135	0.00262	CbGeAlD
Dasatinib—PDGFRB—urethra—rectum cancer	0.00132	0.00258	CbGeAlD
Dasatinib—EPHB6—vagina—rectum cancer	0.00132	0.00257	CbGeAlD
Dasatinib—TESK1—lymph node—rectum cancer	0.0013	0.00253	CbGeAlD
Dasatinib—KIT—mammalian vulva—rectum cancer	0.00129	0.00251	CbGeAlD
Dasatinib—STK36—lymph node—rectum cancer	0.00128	0.00249	CbGeAlD
Dasatinib—EPHB3—lymph node—rectum cancer	0.00128	0.00249	CbGeAlD
Dasatinib—YES1—vagina—rectum cancer	0.00127	0.00248	CbGeAlD
Dasatinib—PDGFRB—mammalian vulva—rectum cancer	0.00126	0.00245	CbGeAlD
Dasatinib—PDGFRA—vagina—rectum cancer	0.00125	0.00243	CbGeAlD
Dasatinib—ABL1—smooth muscle tissue—rectum cancer	0.00125	0.00243	CbGeAlD
Dasatinib—MAP2K5—female reproductive system—rectum cancer	0.00125	0.00243	CbGeAlD
Dasatinib—LIMK2—lymph node—rectum cancer	0.00123	0.0024	CbGeAlD
Dasatinib—CSF1R—female reproductive system—rectum cancer	0.00122	0.00237	CbGeAlD
Dasatinib—ABL1—renal system—rectum cancer	0.0012	0.00234	CbGeAlD
Dasatinib—STK35—lymph node—rectum cancer	0.0012	0.00233	CbGeAlD
Dasatinib—CSK—lymph node—rectum cancer	0.00119	0.00231	CbGeAlD
Dasatinib—ABL1—urethra—rectum cancer	0.00118	0.0023	CbGeAlD
Dasatinib—HCK—lymph node—rectum cancer	0.00117	0.00228	CbGeAlD
Dasatinib—ABL2—lymph node—rectum cancer	0.00117	0.00227	CbGeAlD
Dasatinib—MAP2K5—vagina—rectum cancer	0.00113	0.00219	CbGeAlD
Dasatinib—ABL1—mammalian vulva—rectum cancer	0.00112	0.00219	CbGeAlD
Dasatinib—KIT—female reproductive system—rectum cancer	0.0011	0.00215	CbGeAlD
Dasatinib—RIPK2—lymph node—rectum cancer	0.0011	0.00215	CbGeAlD
Dasatinib—CSF1R—vagina—rectum cancer	0.0011	0.00214	CbGeAlD
Dasatinib—PDGFRB—female reproductive system—rectum cancer	0.00108	0.0021	CbGeAlD
Dasatinib—SIK1—lymph node—rectum cancer	0.00108	0.0021	CbGeAlD
Dasatinib—EPHA4—lymph node—rectum cancer	0.00107	0.00208	CbGeAlD
Dasatinib—CYP1B1—smooth muscle tissue—rectum cancer	0.00106	0.00206	CbGeAlD
Dasatinib—ERBB3—lymph node—rectum cancer	0.00106	0.00206	CbGeAlD
Dasatinib—MAP3K2—lymph node—rectum cancer	0.00105	0.00204	CbGeAlD
Dasatinib—CYP1B1—renal system—rectum cancer	0.00102	0.00198	CbGeAlD
Dasatinib—KIT—vagina—rectum cancer	0.000999	0.00194	CbGeAlD
Dasatinib—MAPK14—lymph node—rectum cancer	0.000983	0.00191	CbGeAlD
Dasatinib—FGR—lymph node—rectum cancer	0.000979	0.00191	CbGeAlD
Dasatinib—LCK—lymph node—rectum cancer	0.000979	0.00191	CbGeAlD
Dasatinib—PDGFRB—vagina—rectum cancer	0.000976	0.0019	CbGeAlD
Dasatinib—ABL1—female reproductive system—rectum cancer	0.000962	0.00187	CbGeAlD
Dasatinib—FMO3—lymph node—rectum cancer	0.000946	0.00184	CbGeAlD
Dasatinib—ABCG2—seminal vesicle—rectum cancer	0.00094	0.00183	CbGeAlD
Dasatinib—EPHB4—lymph node—rectum cancer	0.000932	0.00181	CbGeAlD
Dasatinib—JAK2—lymph node—rectum cancer	0.000926	0.0018	CbGeAlD
Dasatinib—EPHA2—lymph node—rectum cancer	0.000915	0.00178	CbGeAlD
Dasatinib—FYN—lymph node—rectum cancer	0.000913	0.00178	CbGeAlD
Dasatinib—MAP4K5—lymph node—rectum cancer	0.000892	0.00174	CbGeAlD
Dasatinib—MAP3K3—lymph node—rectum cancer	0.000892	0.00174	CbGeAlD
Dasatinib—ABL1—vagina—rectum cancer	0.00087	0.00169	CbGeAlD
Dasatinib—EPHB6—lymph node—rectum cancer	0.000853	0.00166	CbGeAlD
Dasatinib—YES1—lymph node—rectum cancer	0.000824	0.0016	CbGeAlD
Dasatinib—CYP1B1—female reproductive system—rectum cancer	0.000814	0.00158	CbGeAlD
Dasatinib—PDGFRA—lymph node—rectum cancer	0.000808	0.00157	CbGeAlD
Dasatinib—SRC—lymph node—rectum cancer	0.000793	0.00154	CbGeAlD
Dasatinib—CYP1A1—epithelium—rectum cancer	0.000775	0.00151	CbGeAlD
Dasatinib—ABCG2—urethra—rectum cancer	0.000744	0.00145	CbGeAlD
Dasatinib—MAP2K5—lymph node—rectum cancer	0.000729	0.00142	CbGeAlD
Dasatinib—CYP1A2—renal system—rectum cancer	0.000729	0.00142	CbGeAlD
Dasatinib—CYP1A1—renal system—rectum cancer	0.000719	0.0014	CbGeAlD
Dasatinib—CSF1R—lymph node—rectum cancer	0.000712	0.00138	CbGeAlD
Dasatinib—ABCG2—mammalian vulva—rectum cancer	0.000708	0.00138	CbGeAlD
Dasatinib—CYP1A1—urethra—rectum cancer	0.000706	0.00137	CbGeAlD
Dasatinib—CYP3A5—renal system—rectum cancer	0.000703	0.00137	CbGeAlD
Dasatinib—CYP1A1—mammalian vulva—rectum cancer	0.000672	0.00131	CbGeAlD
Dasatinib—KIT—lymph node—rectum cancer	0.000646	0.00126	CbGeAlD
Dasatinib—PDGFRB—lymph node—rectum cancer	0.000631	0.00123	CbGeAlD
Dasatinib—CYP1A1—female reproductive system—rectum cancer	0.000576	0.00112	CbGeAlD
Dasatinib—ABL1—lymph node—rectum cancer	0.000562	0.00109	CbGeAlD
Dasatinib—ABCG2—vagina—rectum cancer	0.000548	0.00107	CbGeAlD
Dasatinib—CYP3A4—renal system—rectum cancer	0.000527	0.00103	CbGeAlD
Dasatinib—CYP1A1—vagina—rectum cancer	0.000521	0.00101	CbGeAlD
Dasatinib—CYP3A5—vagina—rectum cancer	0.000509	0.000991	CbGeAlD
Dasatinib—CYP1B1—lymph node—rectum cancer	0.000476	0.000927	CbGeAlD
Dasatinib—ABCB1—seminal vesicle—rectum cancer	0.000463	0.000902	CbGeAlD
Dasatinib—CYP3A4—female reproductive system—rectum cancer	0.000422	0.000822	CbGeAlD
Dasatinib—ABCB1—epithelium—rectum cancer	0.000403	0.000783	CbGeAlD
Dasatinib—ABCB1—renal system—rectum cancer	0.000373	0.000727	CbGeAlD
Dasatinib—ABCB1—urethra—rectum cancer	0.000367	0.000714	CbGeAlD
Dasatinib—ABCG2—lymph node—rectum cancer	0.000355	0.00069	CbGeAlD
Dasatinib—ABCB1—mammalian vulva—rectum cancer	0.000349	0.00068	CbGeAlD
Dasatinib—CYP1A1—lymph node—rectum cancer	0.000337	0.000655	CbGeAlD
Dasatinib—ABCB1—female reproductive system—rectum cancer	0.000299	0.000582	CbGeAlD
Dasatinib—ABCB1—vagina—rectum cancer	0.00027	0.000526	CbGeAlD
Dasatinib—ABCB1—lymph node—rectum cancer	0.000175	0.00034	CbGeAlD
Dasatinib—HCK—Immune System—NRAS—rectum cancer	6.14e-05	0.000126	CbGpPWpGaD
Dasatinib—LCK—Cytokine Signaling in Immune system—HRAS—rectum cancer	6.12e-05	0.000126	CbGpPWpGaD
Dasatinib—JAK2—Developmental Biology—NRAS—rectum cancer	6.07e-05	0.000125	CbGpPWpGaD
Dasatinib—MAPK14—Hemostasis—NRAS—rectum cancer	6.03e-05	0.000124	CbGpPWpGaD
Dasatinib—LCK—Signaling by NGF—HRAS—rectum cancer	6.02e-05	0.000124	CbGpPWpGaD
Dasatinib—JAK2—Hemostasis—NRAS—rectum cancer	5.95e-05	0.000122	CbGpPWpGaD
Dasatinib—MAP3K3—Immune System—KRAS—rectum cancer	5.92e-05	0.000122	CbGpPWpGaD
Dasatinib—KIT—Innate Immune System—KRAS—rectum cancer	5.9e-05	0.000121	CbGpPWpGaD
Dasatinib—PDGFRB—Innate Immune System—NRAS—rectum cancer	5.85e-05	0.00012	CbGpPWpGaD
Dasatinib—CSK—Immune System—HRAS—rectum cancer	5.85e-05	0.00012	CbGpPWpGaD
Dasatinib—RIPK2—Immune System—NRAS—rectum cancer	5.78e-05	0.000119	CbGpPWpGaD
Dasatinib—BTK—Immune System—KRAS—rectum cancer	5.76e-05	0.000118	CbGpPWpGaD
Dasatinib—LYN—Innate Immune System—NRAS—rectum cancer	5.73e-05	0.000118	CbGpPWpGaD
Dasatinib—ABL1—Innate Immune System—NRAS—rectum cancer	5.7e-05	0.000117	CbGpPWpGaD
Dasatinib—SRC—Axon guidance—KRAS—rectum cancer	5.67e-05	0.000117	CbGpPWpGaD
Dasatinib—KIT—Adaptive Immune System—KRAS—rectum cancer	5.67e-05	0.000117	CbGpPWpGaD
Dasatinib—HCK—Disease—NRAS—rectum cancer	5.66e-05	0.000117	CbGpPWpGaD
Dasatinib—STAT5B—Immune System—HRAS—rectum cancer	5.66e-05	0.000116	CbGpPWpGaD
Dasatinib—FYN—Innate Immune System—NRAS—rectum cancer	5.64e-05	0.000116	CbGpPWpGaD
Dasatinib—YES1—Innate Immune System—HRAS—rectum cancer	5.62e-05	0.000116	CbGpPWpGaD
Dasatinib—PDGFRB—Adaptive Immune System—NRAS—rectum cancer	5.62e-05	0.000116	CbGpPWpGaD
Dasatinib—BMPR1B—Signaling Pathways—TP53—rectum cancer	5.61e-05	0.000115	CbGpPWpGaD
Dasatinib—PDGFRA—Innate Immune System—KRAS—rectum cancer	5.59e-05	0.000115	CbGpPWpGaD
Dasatinib—LYN—Developmental Biology—KRAS—rectum cancer	5.58e-05	0.000115	CbGpPWpGaD
Dasatinib—BLK—Immune System—NRAS—rectum cancer	5.56e-05	0.000114	CbGpPWpGaD
Dasatinib—ABL1—Developmental Biology—KRAS—rectum cancer	5.55e-05	0.000114	CbGpPWpGaD
Dasatinib—FGR—Immune System—NRAS—rectum cancer	5.54e-05	0.000114	CbGpPWpGaD
Dasatinib—LYN—Adaptive Immune System—NRAS—rectum cancer	5.5e-05	0.000113	CbGpPWpGaD
Dasatinib—FYN—Developmental Biology—KRAS—rectum cancer	5.49e-05	0.000113	CbGpPWpGaD
Dasatinib—LYN—Hemostasis—KRAS—rectum cancer	5.47e-05	0.000113	CbGpPWpGaD
Dasatinib—ABL1—Hemostasis—KRAS—rectum cancer	5.45e-05	0.000112	CbGpPWpGaD
Dasatinib—MAPK14—Innate Immune System—NRAS—rectum cancer	5.43e-05	0.000112	CbGpPWpGaD
Dasatinib—FYN—Adaptive Immune System—NRAS—rectum cancer	5.41e-05	0.000111	CbGpPWpGaD
Dasatinib—CSK—Disease—HRAS—rectum cancer	5.4e-05	0.000111	CbGpPWpGaD
Dasatinib—YES1—Adaptive Immune System—HRAS—rectum cancer	5.39e-05	0.000111	CbGpPWpGaD
Dasatinib—FYN—Hemostasis—KRAS—rectum cancer	5.39e-05	0.000111	CbGpPWpGaD
Dasatinib—BMPR1B—Signaling Pathways—HRAS—rectum cancer	5.37e-05	0.00011	CbGpPWpGaD
Dasatinib—PDGFRA—Adaptive Immune System—KRAS—rectum cancer	5.37e-05	0.00011	CbGpPWpGaD
Dasatinib—JAK2—Innate Immune System—NRAS—rectum cancer	5.36e-05	0.00011	CbGpPWpGaD
Dasatinib—SRC—Signaling by NGF—HRAS—rectum cancer	5.33e-05	0.00011	CbGpPWpGaD
Dasatinib—MAPK14—Developmental Biology—KRAS—rectum cancer	5.29e-05	0.000109	CbGpPWpGaD
Dasatinib—HCK—Immune System—KRAS—rectum cancer	5.28e-05	0.000109	CbGpPWpGaD
Dasatinib—STAT5B—Disease—HRAS—rectum cancer	5.23e-05	0.000108	CbGpPWpGaD
Dasatinib—JAK2—Developmental Biology—KRAS—rectum cancer	5.22e-05	0.000107	CbGpPWpGaD
Dasatinib—LCK—Hemostasis—NRAS—rectum cancer	5.21e-05	0.000107	CbGpPWpGaD
Dasatinib—CYP1B1—Metabolism—TYMS—rectum cancer	5.19e-05	0.000107	CbGpPWpGaD
Dasatinib—MAPK14—Hemostasis—KRAS—rectum cancer	5.19e-05	0.000107	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—NRAS—rectum cancer	5.17e-05	0.000106	CbGpPWpGaD
Dasatinib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—rectum cancer	5.12e-05	0.000105	CbGpPWpGaD
Dasatinib—JAK2—Hemostasis—KRAS—rectum cancer	5.12e-05	0.000105	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—NRAS—rectum cancer	5.1e-05	0.000105	CbGpPWpGaD
Dasatinib—PDGFRB—Innate Immune System—KRAS—rectum cancer	5.03e-05	0.000104	CbGpPWpGaD
Dasatinib—MAP3K3—Immune System—HRAS—rectum cancer	5.03e-05	0.000103	CbGpPWpGaD
Dasatinib—KIT—Innate Immune System—HRAS—rectum cancer	5.02e-05	0.000103	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—NRAS—rectum cancer	5.01e-05	0.000103	CbGpPWpGaD
Dasatinib—RIPK2—Immune System—KRAS—rectum cancer	4.97e-05	0.000102	CbGpPWpGaD
Dasatinib—LYN—Innate Immune System—KRAS—rectum cancer	4.93e-05	0.000101	CbGpPWpGaD
Dasatinib—ABL1—Innate Immune System—KRAS—rectum cancer	4.91e-05	0.000101	CbGpPWpGaD
Dasatinib—BTK—Immune System—HRAS—rectum cancer	4.89e-05	0.000101	CbGpPWpGaD
Dasatinib—HCK—Disease—KRAS—rectum cancer	4.88e-05	0.0001	CbGpPWpGaD
Dasatinib—LYN—Hemostasis—TP53—rectum cancer	4.87e-05	0.0001	CbGpPWpGaD
Dasatinib—FYN—Innate Immune System—KRAS—rectum cancer	4.85e-05	9.98e-05	CbGpPWpGaD
Dasatinib—ABL1—Hemostasis—TP53—rectum cancer	4.84e-05	9.96e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Adaptive Immune System—KRAS—rectum cancer	4.83e-05	9.94e-05	CbGpPWpGaD
Dasatinib—SRC—Axon guidance—HRAS—rectum cancer	4.82e-05	9.92e-05	CbGpPWpGaD
Dasatinib—KIT—Adaptive Immune System—HRAS—rectum cancer	4.82e-05	9.91e-05	CbGpPWpGaD
Dasatinib—FYN—Hemostasis—TP53—rectum cancer	4.79e-05	9.85e-05	CbGpPWpGaD
Dasatinib—BLK—Immune System—KRAS—rectum cancer	4.79e-05	9.84e-05	CbGpPWpGaD
Dasatinib—FGR—Immune System—KRAS—rectum cancer	4.77e-05	9.81e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Innate Immune System—HRAS—rectum cancer	4.75e-05	9.77e-05	CbGpPWpGaD
Dasatinib—LYN—Developmental Biology—HRAS—rectum cancer	4.74e-05	9.76e-05	CbGpPWpGaD
Dasatinib—LYN—Adaptive Immune System—KRAS—rectum cancer	4.73e-05	9.73e-05	CbGpPWpGaD
Dasatinib—ABCG2—Metabolism—TYMS—rectum cancer	4.72e-05	9.71e-05	CbGpPWpGaD
Dasatinib—ABL1—Developmental Biology—HRAS—rectum cancer	4.72e-05	9.71e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—NRAS—rectum cancer	4.7e-05	9.68e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—NRAS—rectum cancer	4.7e-05	9.68e-05	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—NRAS—rectum cancer	4.69e-05	9.65e-05	CbGpPWpGaD
Dasatinib—MAPK14—Innate Immune System—KRAS—rectum cancer	4.67e-05	9.61e-05	CbGpPWpGaD
Dasatinib—FYN—Developmental Biology—HRAS—rectum cancer	4.67e-05	9.6e-05	CbGpPWpGaD
Dasatinib—FYN—Adaptive Immune System—KRAS—rectum cancer	4.66e-05	9.58e-05	CbGpPWpGaD
Dasatinib—LYN—Hemostasis—HRAS—rectum cancer	4.65e-05	9.57e-05	CbGpPWpGaD
Dasatinib—ABL1—Hemostasis—HRAS—rectum cancer	4.63e-05	9.53e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—NRAS—rectum cancer	4.62e-05	9.49e-05	CbGpPWpGaD
Dasatinib—MAPK14—Hemostasis—TP53—rectum cancer	4.61e-05	9.49e-05	CbGpPWpGaD
Dasatinib—JAK2—Innate Immune System—KRAS—rectum cancer	4.61e-05	9.49e-05	CbGpPWpGaD
Dasatinib—FYN—Hemostasis—HRAS—rectum cancer	4.58e-05	9.42e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Adaptive Immune System—HRAS—rectum cancer	4.56e-05	9.38e-05	CbGpPWpGaD
Dasatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—rectum cancer	4.55e-05	9.37e-05	CbGpPWpGaD
Dasatinib—JAK2—Hemostasis—TP53—rectum cancer	4.55e-05	9.36e-05	CbGpPWpGaD
Dasatinib—LCK—Adaptive Immune System—NRAS—rectum cancer	4.51e-05	9.27e-05	CbGpPWpGaD
Dasatinib—MAPK14—Developmental Biology—HRAS—rectum cancer	4.5e-05	9.25e-05	CbGpPWpGaD
Dasatinib—HCK—Immune System—HRAS—rectum cancer	4.49e-05	9.23e-05	CbGpPWpGaD
Dasatinib—LCK—Hemostasis—KRAS—rectum cancer	4.49e-05	9.23e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—NRAS—rectum cancer	4.47e-05	9.2e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—KRAS—rectum cancer	4.45e-05	9.15e-05	CbGpPWpGaD
Dasatinib—JAK2—Developmental Biology—HRAS—rectum cancer	4.44e-05	9.13e-05	CbGpPWpGaD
Dasatinib—MAPK14—Hemostasis—HRAS—rectum cancer	4.41e-05	9.07e-05	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—KRAS—rectum cancer	4.39e-05	9.02e-05	CbGpPWpGaD
Dasatinib—JAK2—Hemostasis—HRAS—rectum cancer	4.35e-05	8.96e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—KRAS—rectum cancer	4.31e-05	8.86e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Innate Immune System—HRAS—rectum cancer	4.28e-05	8.8e-05	CbGpPWpGaD
Dasatinib—RIPK2—Immune System—HRAS—rectum cancer	4.23e-05	8.7e-05	CbGpPWpGaD
Dasatinib—LYN—Innate Immune System—HRAS—rectum cancer	4.19e-05	8.62e-05	CbGpPWpGaD
Dasatinib—ABL1—Innate Immune System—HRAS—rectum cancer	4.17e-05	8.58e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—NRAS—rectum cancer	4.15e-05	8.55e-05	CbGpPWpGaD
Dasatinib—HCK—Disease—HRAS—rectum cancer	4.14e-05	8.52e-05	CbGpPWpGaD
Dasatinib—FYN—Innate Immune System—HRAS—rectum cancer	4.12e-05	8.48e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Adaptive Immune System—HRAS—rectum cancer	4.11e-05	8.45e-05	CbGpPWpGaD
Dasatinib—BLK—Immune System—HRAS—rectum cancer	4.07e-05	8.37e-05	CbGpPWpGaD
Dasatinib—FGR—Immune System—HRAS—rectum cancer	4.05e-05	8.34e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—KRAS—rectum cancer	4.05e-05	8.33e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—KRAS—rectum cancer	4.05e-05	8.33e-05	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—KRAS—rectum cancer	4.04e-05	8.31e-05	CbGpPWpGaD
Dasatinib—LYN—Adaptive Immune System—HRAS—rectum cancer	4.02e-05	8.27e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—NRAS—rectum cancer	3.99e-05	8.22e-05	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—NRAS—rectum cancer	3.99e-05	8.21e-05	CbGpPWpGaD
Dasatinib—LCK—Hemostasis—TP53—rectum cancer	3.99e-05	8.2e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—KRAS—rectum cancer	3.97e-05	8.17e-05	CbGpPWpGaD
Dasatinib—MAPK14—Innate Immune System—HRAS—rectum cancer	3.97e-05	8.17e-05	CbGpPWpGaD
Dasatinib—FYN—Adaptive Immune System—HRAS—rectum cancer	3.96e-05	8.15e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—TP53—rectum cancer	3.95e-05	8.13e-05	CbGpPWpGaD
Dasatinib—JAK2—Innate Immune System—HRAS—rectum cancer	3.92e-05	8.06e-05	CbGpPWpGaD
Dasatinib—LCK—Adaptive Immune System—KRAS—rectum cancer	3.88e-05	7.98e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—KRAS—rectum cancer	3.85e-05	7.92e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—TP53—rectum cancer	3.83e-05	7.88e-05	CbGpPWpGaD
Dasatinib—LCK—Hemostasis—HRAS—rectum cancer	3.81e-05	7.84e-05	CbGpPWpGaD
Dasatinib—CSK—Signaling Pathways—HRAS—rectum cancer	3.78e-05	7.78e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—NRAS—rectum cancer	3.78e-05	7.78e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—NRAS—rectum cancer	3.74e-05	7.69e-05	CbGpPWpGaD
Dasatinib—ERBB3—Immune System—HRAS—rectum cancer	3.73e-05	7.67e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—NRAS—rectum cancer	3.69e-05	7.58e-05	CbGpPWpGaD
Dasatinib—STAT5B—Signaling Pathways—HRAS—rectum cancer	3.66e-05	7.53e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—KRAS—rectum cancer	3.58e-05	7.36e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—TP53—rectum cancer	3.53e-05	7.26e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—NRAS—rectum cancer	3.49e-05	7.18e-05	CbGpPWpGaD
Dasatinib—SRC—Developmental Biology—HRAS—rectum cancer	3.44e-05	7.08e-05	CbGpPWpGaD
Dasatinib—ERBB3—Disease—HRAS—rectum cancer	3.44e-05	7.08e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—KRAS—rectum cancer	3.44e-05	7.07e-05	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—KRAS—rectum cancer	3.43e-05	7.06e-05	CbGpPWpGaD
Dasatinib—LCK—Innate Immune System—HRAS—rectum cancer	3.43e-05	7.06e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—NRAS—rectum cancer	3.42e-05	7.03e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—NRAS—rectum cancer	3.42e-05	7.03e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—NRAS—rectum cancer	3.41e-05	7.01e-05	CbGpPWpGaD
Dasatinib—CYP3A5—Metabolism—TYMS—rectum cancer	3.38e-05	6.96e-05	CbGpPWpGaD
Dasatinib—SRC—Hemostasis—HRAS—rectum cancer	3.38e-05	6.94e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—NRAS—rectum cancer	3.33e-05	6.86e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—NRAS—rectum cancer	3.32e-05	6.83e-05	CbGpPWpGaD
Dasatinib—LCK—Adaptive Immune System—HRAS—rectum cancer	3.3e-05	6.78e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—NRAS—rectum cancer	3.29e-05	6.78e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—NRAS—rectum cancer	3.28e-05	6.75e-05	CbGpPWpGaD
Dasatinib—YES1—Immune System—HRAS—rectum cancer	3.27e-05	6.73e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—KRAS—rectum cancer	3.25e-05	6.69e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—KRAS—rectum cancer	3.22e-05	6.61e-05	CbGpPWpGaD
Dasatinib—CYP1A1—Metabolism—TYMS—rectum cancer	3.2e-05	6.57e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—KRAS—rectum cancer	3.17e-05	6.53e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—NRAS—rectum cancer	3.16e-05	6.5e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—NRAS—rectum cancer	3.14e-05	6.47e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—NRAS—rectum cancer	3.12e-05	6.42e-05	CbGpPWpGaD
Dasatinib—SRC—Innate Immune System—HRAS—rectum cancer	3.04e-05	6.25e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—NRAS—rectum cancer	3.03e-05	6.23e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—KRAS—rectum cancer	3e-05	6.18e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—KRAS—rectum cancer	2.94e-05	6.05e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—KRAS—rectum cancer	2.94e-05	6.05e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—KRAS—rectum cancer	2.93e-05	6.03e-05	CbGpPWpGaD
Dasatinib—KIT—Immune System—HRAS—rectum cancer	2.92e-05	6.01e-05	CbGpPWpGaD
Dasatinib—SRC—Adaptive Immune System—HRAS—rectum cancer	2.92e-05	6e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—NRAS—rectum cancer	2.89e-05	5.95e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—NRAS—rectum cancer	2.88e-05	5.93e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—KRAS—rectum cancer	2.87e-05	5.9e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—TP53—rectum cancer	2.86e-05	5.88e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—KRAS—rectum cancer	2.86e-05	5.88e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—KRAS—rectum cancer	2.84e-05	5.83e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—KRAS—rectum cancer	2.83e-05	5.81e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Immune System—HRAS—rectum cancer	2.77e-05	5.69e-05	CbGpPWpGaD
Dasatinib—RIPK2—Signaling Pathways—HRAS—rectum cancer	2.73e-05	5.62e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—NRAS—rectum cancer	2.73e-05	5.62e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—KRAS—rectum cancer	2.72e-05	5.6e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—KRAS—rectum cancer	2.71e-05	5.57e-05	CbGpPWpGaD
Dasatinib—KIT—Disease—HRAS—rectum cancer	2.7e-05	5.55e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—KRAS—rectum cancer	2.69e-05	5.52e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—TP53—rectum cancer	2.61e-05	5.38e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—KRAS—rectum cancer	2.61e-05	5.37e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—NRAS—rectum cancer	2.58e-05	5.31e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Disease—HRAS—rectum cancer	2.55e-05	5.25e-05	CbGpPWpGaD
Dasatinib—ABCB1—Metabolism—TYMS—rectum cancer	2.55e-05	5.25e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—NRAS—rectum cancer	2.52e-05	5.19e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—TP53—rectum cancer	2.52e-05	5.18e-05	CbGpPWpGaD
Dasatinib—MAP2K5—Signaling Pathways—HRAS—rectum cancer	2.5e-05	5.14e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling by GPCR—HRAS—rectum cancer	2.5e-05	5.14e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Immune System—HRAS—rectum cancer	2.49e-05	5.13e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—KRAS—rectum cancer	2.49e-05	5.12e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—KRAS—rectum cancer	2.48e-05	5.1e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—NRAS—rectum cancer	2.44e-05	5.03e-05	CbGpPWpGaD
Dasatinib—LYN—Immune System—HRAS—rectum cancer	2.44e-05	5.02e-05	CbGpPWpGaD
Dasatinib—ABL1—Immune System—HRAS—rectum cancer	2.43e-05	4.99e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—NRAS—rectum cancer	2.42e-05	4.98e-05	CbGpPWpGaD
Dasatinib—ERBB3—Signaling Pathways—HRAS—rectum cancer	2.41e-05	4.96e-05	CbGpPWpGaD
Dasatinib—FYN—Immune System—HRAS—rectum cancer	2.4e-05	4.94e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—KRAS—rectum cancer	2.35e-05	4.84e-05	CbGpPWpGaD
Dasatinib—MAPK14—Immune System—HRAS—rectum cancer	2.31e-05	4.76e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Disease—HRAS—rectum cancer	2.3e-05	4.73e-05	CbGpPWpGaD
Dasatinib—JAK2—Immune System—HRAS—rectum cancer	2.28e-05	4.7e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—NRAS—rectum cancer	2.23e-05	4.6e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—KRAS—rectum cancer	2.22e-05	4.57e-05	CbGpPWpGaD
Dasatinib—FYN—Disease—HRAS—rectum cancer	2.22e-05	4.56e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—TP53—rectum cancer	2.21e-05	4.55e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—NRAS—rectum cancer	2.2e-05	4.53e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—KRAS—rectum cancer	2.17e-05	4.47e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—NRAS—rectum cancer	2.16e-05	4.43e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—NRAS—rectum cancer	2.12e-05	4.37e-05	CbGpPWpGaD
Dasatinib—YES1—Signaling Pathways—HRAS—rectum cancer	2.12e-05	4.35e-05	CbGpPWpGaD
Dasatinib—JAK2—Disease—HRAS—rectum cancer	2.11e-05	4.34e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—KRAS—rectum cancer	2.1e-05	4.33e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—KRAS—rectum cancer	2.08e-05	4.28e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—NRAS—rectum cancer	2.04e-05	4.2e-05	CbGpPWpGaD
Dasatinib—CYP1A2—Metabolism—TYMS—rectum cancer	2.04e-05	4.19e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—NRAS—rectum cancer	2.02e-05	4.15e-05	CbGpPWpGaD
Dasatinib—LCK—Immune System—HRAS—rectum cancer	2e-05	4.11e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—TP53—rectum cancer	1.98e-05	4.06e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—KRAS—rectum cancer	1.92e-05	3.96e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—KRAS—rectum cancer	1.9e-05	3.9e-05	CbGpPWpGaD
Dasatinib—KIT—Signaling Pathways—HRAS—rectum cancer	1.89e-05	3.89e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—TP53—rectum cancer	1.87e-05	3.85e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—KRAS—rectum cancer	1.86e-05	3.82e-05	CbGpPWpGaD
Dasatinib—LCK—Disease—HRAS—rectum cancer	1.85e-05	3.8e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—KRAS—rectum cancer	1.83e-05	3.76e-05	CbGpPWpGaD
Dasatinib—PDGFRA—Signaling Pathways—HRAS—rectum cancer	1.79e-05	3.68e-05	CbGpPWpGaD
Dasatinib—SRC—Immune System—HRAS—rectum cancer	1.77e-05	3.64e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—NRAS—rectum cancer	1.77e-05	3.64e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—KRAS—rectum cancer	1.76e-05	3.62e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—KRAS—rectum cancer	1.74e-05	3.57e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—TP53—rectum cancer	1.68e-05	3.46e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—TP53—rectum cancer	1.65e-05	3.39e-05	CbGpPWpGaD
Dasatinib—SRC—Disease—HRAS—rectum cancer	1.63e-05	3.36e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—TP53—rectum cancer	1.62e-05	3.34e-05	CbGpPWpGaD
Dasatinib—PDGFRB—Signaling Pathways—HRAS—rectum cancer	1.61e-05	3.31e-05	CbGpPWpGaD
Dasatinib—LYN—Signaling Pathways—HRAS—rectum cancer	1.58e-05	3.24e-05	CbGpPWpGaD
Dasatinib—CYP3A4—Metabolism—TYMS—rectum cancer	1.57e-05	3.24e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—NRAS—rectum cancer	1.56e-05	3.22e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—TP53—rectum cancer	1.56e-05	3.22e-05	CbGpPWpGaD
Dasatinib—FYN—Signaling Pathways—HRAS—rectum cancer	1.55e-05	3.19e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—TP53—rectum cancer	1.54e-05	3.17e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—KRAS—rectum cancer	1.52e-05	3.13e-05	CbGpPWpGaD
Dasatinib—MAPK14—Signaling Pathways—HRAS—rectum cancer	1.5e-05	3.08e-05	CbGpPWpGaD
Dasatinib—JAK2—Signaling Pathways—HRAS—rectum cancer	1.48e-05	3.04e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—TP53—rectum cancer	1.35e-05	2.78e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—KRAS—rectum cancer	1.35e-05	2.77e-05	CbGpPWpGaD
Dasatinib—LCK—Signaling Pathways—HRAS—rectum cancer	1.29e-05	2.66e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—TP53—rectum cancer	1.2e-05	2.46e-05	CbGpPWpGaD
Dasatinib—SRC—Signaling Pathways—HRAS—rectum cancer	1.14e-05	2.35e-05	CbGpPWpGaD
